Every figure this model derived for SKIN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.
This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.
| Figure | Value | XBRL tag | As at |
|---|---|---|---|
| capex | 817,000 | PaymentsToAcquirePropertyPlantAndEquipment |
2026-06-30 |
| cash | 206,074,000 | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents |
2026-06-30 |
| current assets | 295,241,000 | AssetsCurrent |
2026-06-30 |
| current liabilities | 168,198,000 | LiabilitiesCurrent |
2026-06-30 |
| equity | 55,568,000 | StockholdersEquity |
2026-06-30 |
| interest expense | 25,325,000 | InterestExpenseNonoperating |
2026-06-30 |
| ocf | 21,960,000 | NetCashProvidedByUsedInOperatingActivities |
2026-06-30 |
| revenue | 290,046,000 | RevenueFromContractWithCustomerExcludingAssessedTax |
2026-06-30 |
| sbc | 11,014,000 | ShareBasedCompensation |
2026-06-30 |
The figures themselves rather than their scores — what somebody looking up SKIN on one particular measure came for.
| Ratio | Value |
|---|---|
| cash operating margin | 3.13 |
| current ratio | 1.77 |
| current ratio reported | 1.76 |
| deferred revenue growth | 577.33 |
| dilution pct | -4.7 |
| fcf margin | 7.29 |
| growth cv | 1.73 |
| interest cover | -0.17 |
| operating margin | -1.49 |
| owner earnings margin | 3.49 |
| revenue growth | -6.46 |
| revenue growth per share | -1.84 |
| roic | -3.72 |
| rule of 40 | -7.94 |
| sbc pct revenue | 3.8 |
What this model itself distrusts about SKIN's figures. Written by the derivation as it ran, not added afterwards.